Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Improved Clinical Outcome Following Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children with Cystic Fibrosis.

Chacko A, Wen SC, Hartel G, Kapur N, Wainwright CE, Clark JE.

Pediatr Infect Dis J. 2019 Feb 4. doi: 10.1097/INF.0000000000002274. [Epub ahead of print]

PMID:
30724835
2.

Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis.

Smith DJ, Klein K, Hartel G, Wainwright CE, Bell SC, Anderson GJ, Reid DW.

Gene. 2019 Jan 30;683:12-17. doi: 10.1016/j.gene.2018.10.002. Epub 2018 Oct 3.

PMID:
30291871
3.

Aspergillus and progression of lung disease in children with cystic fibrosis.

Harun SN, Wainwright CE, Grimwood K, Hennig S; Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group.

Thorax. 2019 Feb;74(2):125-131. doi: 10.1136/thoraxjnl-2018-211550. Epub 2018 Oct 1.

PMID:
30275132
4.

Secrets of intercontinental flight.

Fuller RA, Wainwright CE.

Nat Ecol Evol. 2018 Oct;2(10):1523-1524. doi: 10.1038/s41559-018-0693-1. No abstract available.

PMID:
30228342
5.

Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.

Martin LW, Robson CL, Watts AM, Gray AR, Wainwright CE, Bell SC, Ramsay KA, Kidd TJ, Reid DW, Brockway B, Lamont IL.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01789-18. doi: 10.1128/AAC.01789-18. Print 2018 Nov.

PMID:
30201819
6.

Differential expression of genes and receptors in monocytes from patients with cystic fibrosis.

Tarique AA, Sly PD, Cardenas DG, Luo L, Stow JL, Bell SC, Wainwright CE, Fantino E.

J Cyst Fibros. 2018 Aug 31. pii: S1569-1993(18)30744-6. doi: 10.1016/j.jcf.2018.07.012. [Epub ahead of print]

PMID:
30177416
7.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

McColley SA, Konstan MW, Ramsey BW, Stuart Elborn J, Boyle MP, Wainwright CE, Waltz D, Vera-Llonch M, Marigowda G, Jiang JG, Rubin JL.

J Cyst Fibros. 2019 Jan;18(1):94-101. doi: 10.1016/j.jcf.2018.07.011. Epub 2018 Aug 23.

8.

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.

Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group.

Lancet Respir Med. 2018 Jul;6(7):545-553. doi: 10.1016/S2213-2600(18)30202-9. Epub 2018 Jun 7. Erratum in: Lancet Respir Med. 2018 Jul;6(7):e35.

9.

Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei.

Wood ME, Stockwell RE, Johnson GR, Ramsay KA, Sherrard LJ, Kidd TJ, Cheney J, Ballard EL, O'Rourke P, Jabbour N, Wainwright CE, Knibbs LD, Sly PD, Morawska L, Bell SC.

Thorax. 2019 Jan;74(1):87-90. doi: 10.1136/thoraxjnl-2018-211567. Epub 2018 Apr 7.

PMID:
29627800
10.

Ongoing changes in migration phenology and winter residency at Bracken Bat Cave.

Stepanian PM, Wainwright CE.

Glob Chang Biol. 2018 Jul;24(7):3266-3275. doi: 10.1111/gcb.14051. Epub 2018 Feb 14.

PMID:
29442413
11.

Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis.

Wood ME, Stockwell RE, Johnson GR, Ramsay KA, Sherrard LJ, Jabbour N, Ballard E, O'Rourke P, Kidd TJ, Wainwright CE, Knibbs LD, Sly PD, Morawska L, Bell SC.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):348-355. doi: 10.1164/rccm.201707-1457OC.

PMID:
28930641
12.

Extending bioacoustic monitoring of birds aloft through flight call localization with a three-dimensional microphone array.

Stepanian PM, Horton KG, Hille DC, Wainwright CE, Chilson PB, Kelly JF.

Ecol Evol. 2016 Sep 12;6(19):7039-7046. doi: 10.1002/ece3.2447. eCollection 2016 Oct.

13.

The movement of small insects in the convective boundary layer: linking patterns to processes.

Wainwright CE, Stepanian PM, Reynolds DR, Reynolds AM.

Sci Rep. 2017 Jul 14;7(1):5438. doi: 10.1038/s41598-017-04503-0.

14.

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.

Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS.

J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24.

15.

Preserving Lung Function: The Holy Grail in Managing Cystic Fibrosis.

Sly PD, Wainwright CE.

Ann Am Thorac Soc. 2017 Jun;14(6):833-835. doi: 10.1513/AnnalsATS.201703-254ED. No abstract available.

PMID:
28570157
16.

New treatments targeting the basic defects in cystic fibrosis.

Fajac I, Wainwright CE.

Presse Med. 2017 Jun;46(6 Pt 2):e165-e175. doi: 10.1016/j.lpm.2017.01.024. Epub 2017 May 26. Review.

PMID:
28554723
17.

Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep.

Jee AS, Corte TJ, Wort SJ, Eves ND, Wainwright CE, Piper A.

Respirology. 2017 Jul;22(5):1022-1034. doi: 10.1111/resp.13080. Epub 2017 May 25. Review. No abstract available.

PMID:
28544189
18.

CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis.

Tarique AA, Sly PD, Holt PG, Bosco A, Ware RS, Logan J, Bell SC, Wainwright CE, Fantino E.

J Cyst Fibros. 2017 Jul;16(4):475-482. doi: 10.1016/j.jcf.2017.03.011. Epub 2017 Apr 17.

PMID:
28428011
19.

Sources and dynamics of fluorescent particles in hospitals.

Pereira ML, Knibbs LD, He C, Grzybowski P, Johnson GR, Huffman JA, Bell SC, Wainwright CE, Matte DL, Dominski FH, Andrade A, Morawska L.

Indoor Air. 2017 Sep;27(5):988-1000. doi: 10.1111/ina.12380. Epub 2017 May 5.

PMID:
28303606
20.

Inhaled Corticosteroids and Respiratory Infections in Children With Asthma: A Meta-analysis.

Cazeiro C, Silva C, Mayer S, Mariany V, Wainwright CE, Zhang L.

Pediatrics. 2017 Mar;139(3). pii: e20163271. doi: 10.1542/peds.2016-3271. Review.

21.

Targeted therapy for chronic respiratory disease: a new paradigm.

Gibson PG, Peters MJ, Wainwright CE.

Med J Aust. 2017 Feb 20;206(3):136-140. Review.

PMID:
28208047
22.

Loss of ATM in Airway Epithelial Cells Is Associated with Susceptibility to Oxidative Stress.

Yeo AJ, Fantino E, Czovek D, Wainwright CE, Sly PD, Lavin MF.

Am J Respir Crit Care Med. 2017 Aug 1;196(3):391-393. doi: 10.1164/rccm.201611-2210LE. No abstract available.

PMID:
28207280
23.

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler IC, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O'Brien C, O'Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA.

Science. 2016 Nov 11;354(6313):751-757. doi: 10.1126/science.aaf8156.

24.

The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.

Ramsay KA, Sandhu H, Geake JB, Ballard E, O'Rourke P, Wainwright CE, Reid DW, Kidd TJ, Bell SC.

J Cyst Fibros. 2017 Jan;16(1):70-77. doi: 10.1016/j.jcf.2016.07.010. Epub 2016 Aug 8.

25.

A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease.

Johnson GR, Knibbs LD, Kidd TJ, Wainwright CE, Wood ME, Ramsay KA, Bell SC, Morawska L.

PLoS One. 2016 Jul 7;11(7):e0158763. doi: 10.1371/journal.pone.0158763. eCollection 2016.

26.

Diagnosis and early life risk factors for bronchiectasis in cystic fibrosis: a review.

Sly PD, Wainwright CE.

Expert Rev Respir Med. 2016 Sep;10(9):1003-10. doi: 10.1080/17476348.2016.1204915. Epub 2016 Jul 13. Review.

PMID:
27329819
27.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.

Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE; VX-809 TRAFFIC and TRANSPORT study groups.

Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10.

PMID:
27298017
28.

The role of the US Great Plains low-level jet in nocturnal migrant behavior.

Wainwright CE, Stepanian PM, Horton KG.

Int J Biometeorol. 2016 Oct;60(10):1531-1542. Epub 2016 Feb 13.

PMID:
26872654
29.

Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.

Smith DJ, Ramsay KA, Yerkovich ST, Reid DW, Wainwright CE, Grimwood K, Bell SC, Kidd TJ.

Respirology. 2016 Feb;21(2):329-37. doi: 10.1111/resp.12714. Epub 2015 Dec 28.

30.

Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis.

Tai AS, Bell SC, Kidd TJ, Trembizki E, Buckley C, Ramsay KA, David M, Wainwright CE, Grimwood K, Whiley DM.

PLoS One. 2015 Dec 3;10(12):e0144022. doi: 10.1371/journal.pone.0144022. eCollection 2015.

31.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW.

N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466. No abstract available.

PMID:
26510034
32.

Oxygen saturation targets in infants with bronchiolitis.

Wainwright CE, Kapur N.

Lancet. 2015 Sep 12;386(9998):1016-8. doi: 10.1016/S0140-6736(15)00155-5. No abstract available. Erratum in: Lancet. 2015 Oct 10;386(10002):1446.

33.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

34.

Influence of atmospheric properties on detection of wood-warbler nocturnal flight calls.

Horton KG, Stepanian PM, Wainwright CE, Tegeler AK.

Int J Biometeorol. 2015 Oct;59(10):1385-94. doi: 10.1007/s00484-014-0948-8. Epub 2015 Jan 20.

PMID:
25601781
35.

Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years.

Kidd TJ, Ramsay KA, Vidmar S, Carlin JB, Bell SC, Wainwright CE, Grimwood K; ACFBAL Study Investigators.

J Cyst Fibros. 2015 May;14(3):361-9. doi: 10.1016/j.jcf.2014.12.007. Epub 2015 Jan 3.

36.

Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia.

Roder DM, Fong KM, Brown MP, Zalcberg J, Wainwright CE.

Eur J Cancer Care (Engl). 2014 Nov;23(6):721-7. doi: 10.1111/ecc.12242. Epub 2014 Sep 22.

PMID:
25244252
37.

Ivacaftor for patients with cystic fibrosis.

Wainwright CE.

Expert Rev Respir Med. 2014 Oct;8(5):533-8. doi: 10.1586/17476348.2014.951333. Epub 2014 Aug 22. Review.

PMID:
25148205
38.

Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis.

Moodie M, Lal A, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Robertson CF, Tiddens HA, Wainwright CE; Australasian Cystic Fibrosis Bronchoalveolar Lavage Study Investigators.

J Pediatr. 2014 Sep;165(3):564-569.e5. doi: 10.1016/j.jpeds.2014.05.031. Epub 2014 Jul 1.

PMID:
24996984
39.

A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Syrmis MW, Kidd TJ, Moser RJ, Ramsay KA, Gibson KM, Anuj S, Bell SC, Wainwright CE, Grimwood K, Nissen M, Sloots TP, Whiley DM.

BMC Infect Dis. 2014 Jun 5;14:307. doi: 10.1186/1471-2334-14-307.

40.

Electronic care records - can they fulfil their promise?

Wainwright CE, Tullis E.

J Cyst Fibros. 2014 Dec;13(6):608-9. doi: 10.1016/j.jcf.2014.04.009. Epub 2014 May 23. No abstract available.

41.

Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis.

Knibbs LD, Johnson GR, Kidd TJ, Cheney J, Grimwood K, Kattenbelt JA, O'Rourke PK, Ramsay KA, Sly PD, Wainwright CE, Wood ME, Morawska L, Bell SC.

Thorax. 2014 Aug;69(8):740-5. doi: 10.1136/thoraxjnl-2014-205213. Epub 2014 Apr 17.

42.

Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.

Hennig S, McKay K, Vidmar S, O'Brien K, Stacey S, Cheney J, Wainwright CE.

J Cyst Fibros. 2014 Jul;13(4):428-34. doi: 10.1016/j.jcf.2014.01.014. Epub 2014 Feb 22.

43.

Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis.

Ramsay KA, Butler CA, Paynter S, Ware RS, Kidd TJ, Wainwright CE, Bell SC.

J Clin Microbiol. 2013 Dec;51(12):3975-80. doi: 10.1128/JCM.01360-13. Epub 2013 Sep 18.

44.

Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.

Manos J, Hu H, Rose BR, Wainwright CE, Zablotska IB, Cheney J, Turnbull L, Whitchurch CB, Grimwood K, Harmer C, Anuj SN, Harbour C; ACFBAL study group.

Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1583-92. doi: 10.1007/s10096-013-1916-7. Epub 2013 Jul 7.

PMID:
23832143
45.

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordoñez CL, Ahrens R; VX08-770-103 (ENVISION) Study Group.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25. doi: 10.1164/rccm.201301-0153OC.

46.

High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platform.

Syrmis MW, Moser RJ, Kidd TJ, Hunt P, Ramsay KA, Bell SC, Wainwright CE, Grimwood K, Nissen MD, Sloots TP, Whiley DM.

J Med Microbiol. 2013 May;62(Pt 5):734-40. doi: 10.1099/jmm.0.055905-0. Epub 2013 Feb 14.

PMID:
23412772
47.

Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.

Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Rosenfeld M, Tiddens HA, Wainwright CE; ACFBAL Study Investigators.

Thorax. 2013 Jul;68(7):643-51. doi: 10.1136/thoraxjnl-2012-202342. Epub 2013 Jan 23.

48.

Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres.

Kidd TJ, Ramsay KA, Hu H, Marks GB, Wainwright CE, Bye PT, Elkins MR, Robinson PJ, Rose BR, Wilson JW, Grimwood K, Bell SC; ACPinCF Investigator Group.

Eur Respir J. 2013 May;41(5):1091-100. doi: 10.1183/09031936.00060512. Epub 2012 Aug 9.

49.

Comparison of DNA extraction methods for microbial community profiling with an application to pediatric bronchoalveolar lavage samples.

Willner D, Daly J, Whiley D, Grimwood K, Wainwright CE, Hugenholtz P.

PLoS One. 2012;7(4):e34605. doi: 10.1371/journal.pone.0034605. Epub 2012 Apr 13.

50.

Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening.

Hu H, Harmer C, Anuj S, Wainwright CE, Manos J, Cheney J, Harbour C, Zablotska I, Turnbull L, Whitchurch CB, Grimwood K, Rose B; FBAL study investigators.

Clin Microbiol Infect. 2013 Mar;19(3):266-72. doi: 10.1111/j.1469-0691.2012.03770.x. Epub 2012 Feb 13.

Supplemental Content

Loading ...
Support Center